<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.0 20040830//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-14731R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0009653</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cell Biology</subject><subject>Cardiovascular Disorders/Valvular Disease</subject><subject>Cardiovascular Disorders/Vascular Biology</subject><subject>Oncology/Breast Cancer</subject><subject>Ophthalmology/Corneal Disorders</subject><subject>Cell Biology/Extra-Cellular Matrix</subject></subj-group></article-categories><title-group><article-title>Does Plasminogen Activator Inhibitor-1 Drive Lymphangiogenesis?</article-title><alt-title alt-title-type="running-head">PAI-1 in Lymphangiogenesis</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bruy&#x000e8;re</surname><given-names>Fran&#x000e7;oise</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Melen-Lamalle</surname><given-names>Laurence</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Blacher</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Detry</surname><given-names>Beno&#x000ee;t</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Masset</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lecomte</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lambert</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maillard</surname><given-names>Catherine</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>H&#x000f8;yer-Hansen</surname><given-names>Gunilla</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lund</surname><given-names>Leif R.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Foidart</surname><given-names>Jean-Michel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>No&#x000eb;l</surname><given-names>Agn&#x000e8;s</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Laboratory of Tumor and Development Biology, Groupe Interdisciplinaire de G&#x000e9;noprot&#x000e9;omique Appliqu&#x000e9;-Cancer (GIGA-Cancer), University of Li&#x000e8;ge, Li&#x000e8;ge, Belgium</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Ophthalmology, Centre Hospitalier Universitaire (CHU), Li&#x000e8;ge, Belgium</addr-line></aff><aff id="aff3"><label>3</label><addr-line>The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Gynecology, Centre Hospitalier Universitaire (CHU), Li&#x000e8;ge, Belgium</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Cao</surname><given-names>Yihai</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Karolinska Institutet, Sweden</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>agnes.noel@ulg.ac.be</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: JMF AN. Performed the experiments: FB LML BD AM. Analyzed the data: FB SB AM JL CM AN. Contributed reagents/materials/analysis tools: SB JL VL CM GHH LRL JMF AN. Wrote the paper: FB AN.</p></fn></author-notes><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>11</day><month>3</month><year>2010</year></pub-date><volume>5</volume><issue>3</issue><elocation-id>e9653</elocation-id><history><date date-type="received"><day>6</day><month>12</month><year>2009</year></date><date date-type="accepted"><day>16</day><month>2</month><year>2010</year></date></history><permissions><copyright-statement>Bruy&#x000e8;re et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement></permissions><abstract><p>The purpose of this study is to explore the function of plasminogen activator inhibitor-1 (PAI-1) during pathological lymphangiogenesis. PAI-1, the main physiological inhibitor of plasminogen activators is involved in pathological angiogenesis at least by controlling extracellular proteolysis and by regulating endothelial cell survival and migration. Protease system's role in lymphangiogenesis is unknown yet. Thus, based on its important pro-angiogenic effect, we hypothesized that PAI-1 may regulate lymphangiogenesis associated at least with metastatic dissemination of cancer cells. To address this issue, we studied the impact of PAI-1 deficiency in various murine models of tumoral lymphangiogenesis. Wild-type PAI-1 proficient mice were used as controls. We provide for the first time evidence that PAI-1 is dispensable for tumoral lymphangiogenesis associated with breast cancers either induced by mammary carcinoma cell injection or spontaneously appearing in transgenic mice expressing the polyomavirus middle T antigen (PymT) under the control of a mouse mammary tumor virus long-terminal repeat promoter (MMTV-LTR). We also investigated inflammation-related lymphatic vessel recruitment by using two inflammatory models. PAI-1 deficiency did neither affect the development of lymphangioma nor burn-induced corneal lymphangiogenesis. These novel data suggest that vascular remodelling associated with lymphangiogenesis and angiogenesis involve different molecular determinants. PAI-1 does not appear as a potential therapeutic target to counteract pathological lymphangiogenesis.</p></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The lymphatic network is composed of blind-ended lymphatic vessels that regulate tissue homeostasis, the afferent immune response and fat transport. After collecting extravasated protein-rich fluid and lymphocytes from the extracellular space or triglycerides from the gut, lymphatic capillaries transport them back to the blood circulation through larger vessels and lymph nodes <xref ref-type="bibr" rid="pone.0009653-Karpanen1">&#x0005b;1&#x0005d;</xref>. Tumoral cell metastasis may occur by invading either the blood circulation or the lymphatic vascular system. The increased permeability and the absence of basement membrane of lymphatic vessels compared to blood vessels facilitate the intravasation of tumor cells into the lymphatic system. Therefore, lymphatic vessels offer an easy way for cancer cells to disseminate and form metastasis into the lymph nodes before reaching the blood circulation. This is supported by the clinical investigation of the sentinel lymph node while searching for cancer dissemination in patients <xref ref-type="bibr" rid="pone.0009653-Thiele1">&#x0005b;2&#x0005d;</xref>. Moreover, the lymphatic system is involved in chronic inflammatory diseases and in transplant rejection (renal and corneal graft rejection) <xref ref-type="bibr" rid="pone.0009653-Thaunat1">&#x0005b;3&#x0005d;</xref>. Therefore, a better understanding of the molecular and cellular basis of lymphatic abnormalities associated with cancers and inflammation is essential for the development of novel therapeutic strategies.</p><p>Components of the plasminogen activation system are involved in several physiological and pathological processes associated with important tissue remodelling <xref ref-type="bibr" rid="pone.0009653-Dass1">&#x0005b;4&#x0005d;</xref>. This proteolytic system is composed of serine proteases including tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), uPA receptor (uPAR) and the plasminogen activator inhibitors (PAI), the main one being PAI-1. The contribution of these proteins in cancer progression relies on their capacity to control various biological processes such as (i) cell proliferation <xref ref-type="bibr" rid="pone.0009653-Lee1">&#x0005b;5&#x0005d;</xref>; (ii) cell invasion through plasmin-mediated extracellular matrix degradation <xref ref-type="bibr" rid="pone.0009653-Dano1">&#x0005b;6&#x0005d;</xref>; (iii) cell adhesion and migration through the interaction of uPA/uPAR/PAI-1 complex with vitronectin and integrins <xref ref-type="bibr" rid="pone.0009653-Czekay1">&#x0005b;7&#x0005d;</xref>; and (iv) cell apoptosis through the control of pro-apoptotic factor release <xref ref-type="bibr" rid="pone.0009653-Bajou1">&#x0005b;8&#x0005d;</xref>. PAI-1 is now recognized as an essential factor of the host microenvironment that promotes tumor growth, vessel recruitment <xref ref-type="bibr" rid="pone.0009653-Leik1">&#x0005b;9&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0009653-Lambert2">&#x0005b;14&#x0005d;</xref> and dissemination of tumoral cells to distant organs <xref ref-type="bibr" rid="pone.0009653-Ossowski1">&#x0005b;15&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Tsuchiya1">&#x0005b;16&#x0005d;</xref>. The effect of PAI-1 depends on its concentration, being pro-angiogenic at physiological concentration and anti-angiogenic at pharmacological concentrations <xref ref-type="bibr" rid="pone.0009653-Lambert2">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Devy1">&#x0005b;17&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0009653-Bajou3">&#x0005b;19&#x0005d;</xref> These experimental observations confirm the positive correlation existing between PAI-1 blood levels, the rate of metastasis and the poor prognostic of patient with different types of cancers (for review: <xref ref-type="bibr" rid="pone.0009653-Lee1">&#x0005b;5&#x0005d;</xref>). The essential role of PAI-1 in angiogenesis was also demonstrated in a laser-induced model of choroidal angiogenesis that mimics the age-related macular degeneration extending its function to ocular diseases <xref ref-type="bibr" rid="pone.0009653-Lambert1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Lambert2">&#x0005b;14&#x0005d;</xref>.</p><p>Based on its pivotal role during tumoral angiogenesis, a contribution of PAI-1 in lymphangiogenesis is anticipated, but not documented. In the present study, to address this issue, we applied different models of tumoral and inflammation-induced lymphangiogenesis into PAI-1 deficient mice having different genetic backgrounds.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><sec id="s2a"><title>Transgenic Modified Mice</title><p>Homozygous PAI-1 deficient mice (PAI-1<sup>&#x02212;/&#x02212;</sup>) and their corresponding wild type mice (PAI-1 WT) were those previously used for angiogenesis studies with a mixed genetic background of 87&#x00025; C57BL/6 and 13&#x00025; 129SV/SL strain <xref ref-type="bibr" rid="pone.0009653-Bajou1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Devy1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Jost1">&#x0005b;20&#x0005d;</xref>. Their corresponding immunodeficient mice were generated in a RAG-1<sup>&#x02212;/&#x02212;</sup> background and genotyped by PAI-1 and PGKPA gene annealing as previously described <xref ref-type="bibr" rid="pone.0009653-Maillard1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Jost1">&#x0005b;20&#x0005d;</xref>. Heterozygous FVB/N-PyMT male mice obtained from Finsen Laboratory (Copenhagen, Denmark) were mated with homozygous PAI-1<sup>&#x02212;/&#x02212;</sup> and PAI-1 WT female mice, which were backcrossed for eight generations into the FVB/N strain <xref ref-type="bibr" rid="pone.0009653-Almholt1">&#x0005b;21&#x0005d;</xref>. Mouse experimentation was done in accordance to the guidelines of the University of Li&#x000e8;ge regarding the care and use of laboratory animals.</p></sec><sec id="s2b"><title>Cell Lines</title><p>The human MCF-7 breast carcinoma cell line transfected either with human VEGF-C mature form cDNA (MCF-7/VEGF-C) or with control cDNA (MCF-7/EB57II) were obtained from Kari Alitalo (University of Helsinki, Finland) <xref ref-type="bibr" rid="pone.0009653-Karpanen2">&#x0005b;22&#x0005d;</xref>. Cells were routinely cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with GlutaMAX, 25 mM Hepes, penicillin (100 U/ml), streptomycin (100 mg/ml), hygromycin (150 mg/ml) and 10&#x00025; fetal bovine serum (Gibco, Grand Island, NY). Amplification of VEGF-C cDNAs was carried out by polymerase chain reaction using the reverse primers: <named-content content-type="gene">TTG-TTC-GCT-GCC-TGA-CAC-TG</named-content> and the forward primers: <named-content content-type="gene">CTC-TCT-CTC-AAG-GCC-CCA-AA</named-content>. The PCR condition was 94&#x000b0;C for 0.15 min, 55&#x000b0;C for 0.2 min, and 72&#x000b0;C for 0.2 min, for 30 cycles. Human VEGF-C ELISA (R&#x00026;D Systems, Minneapolis, MN) was performed on medium conditioned by cells according manufacture's instructions.</p></sec><sec id="s2c"><title>Mammary Orthotopic Transplantation</title><p>Subconfluent MCF7 cultures were harvested by trypsinization, washed twice and resuspended in serum-free medium. Cells (2.5&#x000d7;10<sup>6</sup>/50 &#x000b5;l) were bilaterally inoculated into the fat pads of the fifth mammary glands (mfp) of 8- to 12-week-PAI-1<sup>&#x02212;/&#x02212;</sup> and, -WT RAG-1<sup>&#x02212;/&#x02212;</sup> female mice. Mice were supplemented with a subcutaneous 60-days slow-release pellet containing 0.72 mg of 17&#x000df;-estradiol (Innovative Research of America, Toledo, OH). Tumor growth was measured with a calliper and the volume was calculated according to the formula V&#x0200a;&#x0003d;&#x0200a;(&#x003c0;/6)(d<sub>1</sub>Xd<sub>2</sub>)<sup>3/2</sup><xref ref-type="bibr" rid="pone.0009653-Mattila1">&#x0005b;23&#x0005d;</xref>. After 16 weeks, mice were killed and tumors, lungs and lymph nodes were collected. All the samples were formalin fixed and paraffin embedded. The tumor incidence is defined as the percentage of animals bearing a palpable tumor. Two separate sets of experiments with similar results were performed with each time at least 8 to 11 mice per experimental group; presented data are combined results (34&#x02013;38 injected mammary fat pads (mfp) per condition).</p></sec><sec id="s2d"><title>Tumor Processing in PyMT Mice</title><p>Female mice heterozygous for the PyMT transgene and homozygous for the wild type or mutated PAI-1 gene were used in these studies. After 8, 11 or 14 weeks, mice were killed and tumors, lungs and lymph nodes were collected. Tumors were weighted before formalin fixation and paraffin embedding. To avoid any variance from the fat pad localisation (peritoneal-localised tumors being bigger than those developed in the thoracic cavity), all the individual tumor weights were summed to give the total tumor weight of each mice. The number of mice sacrified per genotype was: 19 for PyMT PAI-1 WT mice and 23 for PyMT PAI-1<sup>&#x02212;/&#x02212;</sup> mice sacrified at 14 weeks; 17 for PyMT PAI-1 WT mice and 9 for PyMT PAI-1<sup>&#x02212;/&#x02212;</sup> mice sacrified at 11 weeks and 12 for PyMT PAI-1 WT mice, and 7 for PyMT PAI-1<sup>&#x02212;/&#x02212;</sup> sacrified at 8 weeks.</p></sec><sec id="s2e"><title>Lymphangioma</title><p>Lymphatic endothelial hyperplasia (lymphangioma) formation was induced by two intraperitoneal injections of incomplete Freund's adjuvant <xref ref-type="bibr" rid="pone.0009653-Mancardi1">&#x0005b;24&#x0005d;</xref>. For ethical purposes, buprenorphine hydrochloride injections (0.05 mg/kg, TEMGESIC&#x000ae;, Reckitt Benckiser, UK) were administered every 12 h during the first 5 days 1 h before and after adjuvant injections. After 4 weeks, mice (n&#x0200a;&#x0003d;&#x0200a;6) were killed and lymphangioma masses appearing at the surface of diaphragm were photographed for quantification using the ImageJ 1.40 g software (NIH). The lymphangioma development was determined by reporting the lymphangioma surface on the total organ area. The lymphatic origin of tumors was assessed by positivity for LYVE-1 as described above. Sirius Red staining was obtained by incubating the deparaffinised and ionised slides with 0.1&#x00025; Sirius Red (Polyscience, Warrington, PA)/picric acid (1.15 g/100 ml). Slides were then rapidly incubated in 90&#x00025; alcohol and in xylene before being mounted with Eukitt medium.</p></sec><sec id="s2f"><title>Immunohistochemistry on Slides and Metastasis Detection</title><p>All reagents and procedure are summarized in <xref ref-type="table" rid="pone-0009653-t001">Table 1</xref>. In brief, after deparaffination and rehydration, immunostainings were performed on 6 &#x000b5;m slides by first unmasking antigens and subsequently blocking endogenous peroxidases by 3&#x00025; H<sub>2</sub>O<sub>2</sub>/H<sub>2</sub>O for 20 min. Nonspecific binding was prevented by a specific treatment before the incubation with primary and secondary (if needed) antibodies followed by incubation with a streptavidin/HRP complex (DAKO, Glostrup, Denmark, 1/500) at room temperature (RT) for 30 min. Slides were stained with 3-3&#x02032;diaminobenzidine hydrochloride (DAKO, Glostrup, Denmark) for 3 min to 10 min, counterstained with hematoxylin and mounted with Eukitt medium for microscope observation. Omission of the first antibody served as negative control.</p><table-wrap id="pone-0009653-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009653.t001</object-id><label>Table 1</label><caption><title>Antibodies and procedure used for immunochemistry to detect metastasis on lung and lymph node slides, lymphatic vessels and inflammatory cells on primary tumors/lymphangiomas.</title></caption><alternatives><graphic id="pone-0009653-t001-1" xlink:href="pone.0009653.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="4" align="left" rowspan="1">Steps of immunohistochemistry</td></tr><tr><td align="left" rowspan="1" colspan="1">Antibody used</td><td align="left" rowspan="1" colspan="1">Unmasking</td><td align="left" rowspan="1" colspan="1">Blockage</td><td align="left" rowspan="1" colspan="1">Primary antibodies</td><td align="left" rowspan="1" colspan="1">Secondary antibodies</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Detection of MCF7 tumor metastasis in lymph nodes and lungs.</bold></td><td align="left" rowspan="1" colspan="1">0.05&#x00025; H<sub>2</sub>O<sub>2</sub>/trypsin, 40 min at 37&#x000b0;C</td><td align="left" rowspan="1" colspan="1">PBS/bovine serum albumin 0&#x00025; (Fraction V, Acros Organics1, NJ), 1 hour</td><td align="left" rowspan="1" colspan="1">Mouse anti-human pS2 protein (1/50, 1h30 at RT) (DAKO, Glostrup, Denmark)</td><td align="left" rowspan="1" colspan="1">Goat anti-mouse Envision/HRP (30 min at RT) (DAKO, Glostrup, Denmark)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Detection of MCF7 tumor metastasis in lymph nodes.</bold></td><td align="left" rowspan="1" colspan="1">0.05&#x00025; H<sub>2</sub>O<sub>2</sub>/pronase, 10 min at RT</td><td align="left" rowspan="1" colspan="1">normal goat serum, 30 min</td><td align="left" rowspan="1" colspan="1">Rabbit anti-cytokeratin WSS (Wide Spectrum Screening) (1/500, 1 h at 37&#x000b0;C) (DAKO, Glostrup, Denmark)</td><td align="left" rowspan="1" colspan="1">Goat anti-rabbit/biotine (1/400, 30 min at RT) (DAKO, Glostrup, Denmark)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Detection of MCF7 tumor metastasis in lungs.</bold></td><td align="left" rowspan="1" colspan="1">Target Retrieval Solution (DAKO, Glostrup, Denmark), 11 min at 126&#x000b0;C</td><td align="left" rowspan="1" colspan="1">H<sub>2</sub>O<sub>2</sub>/Universal Blocking Reagent (1/10, BioGenex, San Ramon, USA), 10 min</td><td align="left" rowspan="1" colspan="1">Rat anti-Ki-67 (1/50, 1 h at RT), (DAKO, Glostrup, Denmark)</td><td align="left" rowspan="1" colspan="1">Rabbit anti-rat/biotine (1/300, 30 podoplaninmin at RT), (DAKO, Glostrup, Denmark)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Detection of PyMT tumor metastasis in lymph nodes.</bold></td><td align="left" rowspan="1" colspan="1">Citrate buffer (pH 6), 11 min at 126&#x000b0;C</td><td align="left" rowspan="1" colspan="1">H<sub>2</sub>O<sub>2</sub>/Universal Blocking Reagent (1/10, BioGenex, San Ramon, USA), 10 min</td><td align="left" rowspan="1" colspan="1">Rabbit anti-cytokeratin 8 (1/100, 1 h at RT) (Abcam, Cambridge, PA)</td><td align="left" rowspan="1" colspan="1">Goat anti-rabbit/biotine (1/400, 30 min at RT) (DAKO, Glostrup, Denmark)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Detection of lymphatic vessels</bold></td><td align="left" rowspan="1" colspan="1">Target Retrieval Solution (DAKO, Glostrup, Denmark), 11 min at 126&#x000b0;C</td><td align="left" rowspan="1" colspan="1">PBS/bovine serum albumin 10&#x00025; (Fraction V, Acros Organics, NJ), 1 h</td><td align="left" rowspan="1" colspan="1">Rabbit anti-Lyve-1 (1/1000, 1h30 at RT) (Upstate, Lake Placid, NY)</td><td align="left" rowspan="1" colspan="1">Goat anti-rabbit/biotine (1/400, 30 min at RT) (DAKO, Glostrup, Denmark)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Detection of lymphatic vessels</bold></td><td align="left" rowspan="1" colspan="1">Citrate buffer (pH 6), 11 min at 126&#x000b0;C</td><td align="left" rowspan="1" colspan="1">normal goat serum, 30 min</td><td align="left" rowspan="1" colspan="1">Syrian hamster anti-podoplanin (1/1000, 1 h at RT) (Reliatech, Braunschweig, Germany)</td><td align="left" rowspan="1" colspan="1">Goat anti-syrian hamster/biotine podoplanin(1/500, 30 min at RT) (Jackson ImmunoResearch, podoplaninBaltimore, US)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Detection of inflammatory cells</bold></td><td align="left" rowspan="1" colspan="1">Citrate buffer (pH 6), 11 min at 126&#x000b0;C</td><td align="left" rowspan="1" colspan="1">H<sub>2</sub>O<sub>2</sub>/Universal Blocking Reagent (1/10, BioGenex, San Ramon, USA), 10 min</td><td align="left" rowspan="1" colspan="1">Mouse anti CD45/biotine podoplanin(1/500, 1 h at RT) (Pharmingen, San Diego, USA)</td><td align="left" rowspan="1" colspan="1">Amplification with biotinylated tyramide (PerkinElmer, MA, USA)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>RT&#x0200a;&#x0003d;&#x0200a;Room temperature.</p></fn></table-wrap-foot></table-wrap><p>Metastases in the lymph nodes and in lungs of mice bearing MCF7 tumors or PyMT mice were detected by immunostaining (<xref ref-type="table" rid="pone-0009653-t001">Table 1</xref>). Results are expressed as the percentage of animals presenting at least one metastatic nodule.</p></sec><sec id="s2g"><title>Computerized Vessel Quantification in Tumors and Lymphangioma</title><p>ImageJ software (NIH) was used to first manually delineate the immunolabelled vessels. We binarized images and optimized the threshold to highlight the vessels. For mammary tumors, the following parameters were determined on the whole tumor section: the relative vascular area (lymphatic vessel area reported to the total area of the tumor (&#x000b5;m<sup>2</sup>/&#x000b5;m<sup>2</sup>)), the number of sections of lymphatic vessels (reported to the total area of the tumor (1/&#x000b5;m<sup>2</sup>)) and the mean vessel area (lymphatic vessel area divided by the number of vessels (&#x000b5;m<sup>2</sup>)). For lymphangiomas, due to the variation in lymphangioma width associated with different fibrotic reaction, vessel quantifications are expressed by total vessel area (&#x000b5;m<sup>2</sup>) (at least 3 images were analyzed per sample (n&#x0200a;&#x0003d;&#x0200a;6)).</p></sec><sec id="s2h"><title>Corneal Assay</title><p>Corneal lymphangiogenesis was induced by thermal cauterization of the central cornea by using an ophthalmic cautery (OPTEMP II V, Alcon Surgial, Fort Worth, USA). Seven days later, mice were sacrificed, eyes were removed and corneas were flat mounted (n&#x0200a;&#x0003d;&#x0200a;5, one flat mount per mice). Whole corneas were stained after fixation in ethanol 70&#x00025;. Cornea whole mounts were blocked in 1,5&#x00025; BSA-3&#x00025; Gloria milk for 1 h at RT and incubated overnight with rabbit anti-LYVE-1 (1/600, a kind gift from Dr. K. Alitalo, Finland). After four 10 min washes with PBS, corneas were incubated with the FITC-coupled swine anti-rabbit Ig (1/40; DAKO, Glostrup, Denmark) for 60 min at RT and whole-mounted on a microscope slide with Vectashield-DAPI mounting medium (Vector Laboratories, Burlingame, CA). The area covered by immunostained lymphatic vessels was determined and normalized to the total corneal area. We also measured the length densities defined as the total area occupied by lymphatic network and the cumulative length of vessels. For both parameters, results are expressed per corneal area unit (&#x000b5;m<sup>2</sup>). As the mechanism of vascular growth is sprouting, its extent can be detected by the increase of vessel network extremities, which corresponds to the number of smallest vessels (so-called first order vessels in the centripetal ordering method) <xref ref-type="bibr" rid="pone.0009653-Fenton1">&#x0005b;25&#x0005d;</xref>. To achieve this, we determined the end-point density defined as the vessel network extremity number per corneal area unit. The branching density (defined as the vessel branching number per corneal area unit) was also measured to evaluate the degree of the vessel tree complexity <xref ref-type="bibr" rid="pone.0009653-Blacher1">&#x0005b;26&#x0005d;</xref>.</p></sec><sec id="s2i"><title>Statistical Analysis</title><p>Statistical analyses were performed using GraphPad PRISM 4 software. Incidences were evaluated as contingency table by Fisher's exact test. Other variables were tested by a one-way ANOVA (Kruskal-Wallis test) followed by the Mann Whitney test in order to avoid multiplicity. These tests were also used to determine significance in the morphometric analyses. Results are expressed &#x000b1; S.E.M. Differences were considered statistically significant for <italic>P</italic> values less than or equal to 0.05.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>PAI-1 Is Dispensable for Lymphangiogenesis in an Experimental Model of Breast Cancer</title><p>To test the impact of PAI-1 on lymphatic vessel recruitment in tumors, VEGF-C-overexpressing MCF7 cells or control MCF7 cells were bilaterally injected into the fifth mammary fat pads (mfp) of immunodeficient RAG-1<sup>&#x02212;/&#x02212;</sup> mice that are deficient in PAI-1 (PAI-1<sup>&#x02212;/&#x02212;</sup>) or not (PAI-1 WT). We checked the production of VEGF-C by the tumor cells in culture by RT-PCR (<xref ref-type="fig" rid="pone-0009653-g001">Fig. 1A</xref>) and in supernatants by ELISA (data not shown). Mice were supplemented with oestrogen by the subcutaneous implantation of oestradiol releasing pellets. Two separate sets of experiments with similar results were performed with at least 8 to 10 mice per experimental group (34&#x02013;38 mfp per condition). At week 16, both PAI-1 WT and PAI-1<sup>&#x02212;/&#x02212;</sup> mice implanted with VEGF-C expressing cells showed higher tumor incidence (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.0051, <italic>P</italic>&#x0003c;0.0001, respectively; <xref ref-type="fig" rid="pone-0009653-g001">Fig. 1B</xref>) and, in PAI-1 WT mice, a tendency to a higher tumor volume (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.1513; <xref ref-type="fig" rid="pone-0009653-g001">Fig. 1C</xref>) than mice inoculated with mock MCF7 cells. It is worth noting that the effect of VEGF-C on tumoral volume didn't reached the statistical significance due to the low number of tumors detected in mice injected with the non-VEGF-C producing cells (3 out of 38 mfp). Interestingly, PAI-1 deficiency reduced the incidence of tumors developed both in the presence of VEGF-C expression (52&#x00025; of VEGF-C expressing tumors in PAI-1 WT mice <italic>versus</italic> 22&#x00025; in PAI-1<sup>&#x02212;/&#x02212;</sup> mice) (<italic>P</italic>&#x0003c;0.0089) and in its absence (8&#x00025; of control tumors in PAI-1 WT mice <italic>versus</italic> 0&#x00025; in PAI-1<sup>&#x02212;/&#x02212;</sup> mice) (<xref ref-type="fig" rid="pone-0009653-g001">Fig. 1B</xref>). When considering the volume of tumors, differences did not reach statistical differences between PAI-1 WT and PAI-1<sup>&#x02212;/&#x02212;</sup> mice (<xref ref-type="fig" rid="pone-0009653-g001">Fig. 1C</xref>).</p><fig id="pone-0009653-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009653.g001</object-id><label>Figure 1</label><caption><title>Tumor development after orthotopic injection of VEGF-C overexpressing MCF7 cells or control MCF7 cells implanted in the mammary fat pads (mfp) of PAI-1 WT or PAI-1<sup>&#x02212;/&#x02212;</sup> mice.</title><p>(A): RT-PCR analysis of VEGF-C and 28S mRNA expression by MCF7. (B): Tumor incidence (&#x00025;) is defined as the percentage of palpable tumor per mfp. (C): Tumor volume was measured as described in Material and <xref ref-type="sec" rid="s2">Methods</xref>. (D): Representative figure of a typical metastasis in lymph node (left) and lung (right). (E): Percentage of animal bearing at least a tumor nodule (metastasis&#x00025; detected in lymph nodes (black boxes) and lungs (white boxes). Number of mfp per condition&#x0200a;&#x0003d;&#x0200a;34&#x02013;38. The mice PAI-1 status (WT or &#x02212;/&#x02212;) and the VEGF-C production (VEGF-C) or not (Ctl) by MCF7 cells are indicated below each graph. Data are &#x000b1; S.E.M. Scale bars: 200 &#x000b5;m. &#x0002a;&#x0002a; P&#x02264;0.01, &#x0002a;&#x0002a;&#x0002a; P&#x02264;0.001, NS&#x0200a;&#x0003d;&#x0200a;Non Significant.</p></caption><graphic xlink:href="pone.0009653.g001"/></fig><p>The metastatic ability of cells was assessed by immunochemical staining with antibodies raised against pS2 protein and cytokeratin WSS on lymph node sections or against pS2 protein and Ki-67 on lung sections. Histological examination in the lung (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.2879) or the lymph nodes (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.1037) of mice bearing a VEGF-C expressing tumor revealed similar metastasis incidence for the two different groups (PAI-1 WT or PAI-1<sup>&#x02212;/&#x02212;</sup> mice) (<xref ref-type="fig" rid="pone-0009653-g001">Fig. 1D, E</xref>).</p><p>The lymphatic vasculature was next investigated on primary tumors (<xref ref-type="fig" rid="pone-0009653-g002">Fig. 2A</xref>). Through Lyve-1 immunolabeling on tumor sections, quantification performed by computerized image analysis led to the determination of 3 different parameters (<xref ref-type="fig" rid="pone-0009653-g002">Fig. 2B, C, D</xref>). In accordance to previous report <xref ref-type="bibr" rid="pone.0009653-Mattila1">&#x0005b;23&#x0005d;</xref>, VEGF-C over-expressing tumors displayed a higher relative vasculature area than control tumors. However, the VEGF-C-induced lymphatic vasculature was similar in PAI-1 WT and PAI-1<sup>&#x02212;/&#x02212;</sup> mice (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.4048) (<xref ref-type="fig" rid="pone-0009653-g002">Fig. 2B</xref>). Because of the very low number of tumors developed in the absence of VEGF-C (3 out of 38 mfp in PAI-1 WT mice and 0 out of 34 mfp in PAI-1<sup>&#x02212;/&#x02212;</sup> mice), no comparison could be performed between the two genotypes. This increased lymphatic vessel area observed in the presence of VEGF-C relied on an increased vessel number (<xref ref-type="fig" rid="pone-0009653-g002">Fig. 2C</xref>) while vessel size was unchanged (<xref ref-type="fig" rid="pone-0009653-g002">Fig. 2D</xref>).</p><fig id="pone-0009653-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009653.g002</object-id><label>Figure 2</label><caption><title>Analysis of intratumoral lymphatic vessels in tumors induced by orthotopic injection of VEGF-C overexpressing MCF7 or control MCF7 cells implanted in the mammary fat pads (mfp) of PAI-1 WT or PAI-1<sup>&#x02212;/&#x02212;</sup> mice.</title><p>(A): Representative images of Lyve-1 positive-vessels at two different magnifications in VEGF-C expressing tumors developed in WT mice (WT) or PAI-1 deficient mice (<sup>&#x02212;/&#x02212;</sup>), and in control tumors (Ctl). (B&#x02013;D): Quantification of lymphatic vessels has been performed by computerized image analysis and led to the determination of three parameters: 1- relative vascular area (area occupied by intratumoral lymphatic vessels reported to the total tumor surface) (B); 2- number of lymphatic vessel sections per slide (number of vessels) (C) and; 3- mean lymphatic vessel size (D). The mice PAI-1 status (WT or &#x02212;/&#x02212;) and the VEGF-C production (VEGF-C) or not (Ctl) by MCF7 cells are indicated below each graph. Data are &#x000b1; S.E.M. NS&#x0200a;&#x0003d;&#x0200a;Non Significant.</p></caption><graphic xlink:href="pone.0009653.g002"/></fig></sec><sec id="s3b"><title>PAI-1 Is Dispensable for Lymphangiogenesis and Metastatic Dissemination in a Spontaneous Model of Breast Tumors</title><p>In order to further analyse the role of PAI-1 in tumor growth and metastatic dissemination, we used transgenic PyMT mice that spontaneously develop mammary tumors. PyMT mice were crossed with PAI-1 WT or PAI-1<sup>&#x02212;/&#x02212;</sup> mice in a FVB/N background. At week 8 or 11, difference was observed neither in tumor incidence (100&#x00025;) nor in tumor weight (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.8875; <xref ref-type="fig" rid="pone-0009653-g003">Fig. 3A</xref>). A very slight increase of tumor weight was even observed after 14 weeks in PAI-1 KO mice (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.0461). Histochemical and immunochemical analyses detecting cytokeratin 8 and Ki67 did not reveal any difference in the metastatic dissemination into the lung or lymph nodes between PyMT PAI-1 WT and PyMT PAI-1<sup>&#x02212;/&#x02212;</sup> mice sacrified after 14 weeks (<xref ref-type="fig" rid="pone-0009653-g003">fig. 3B</xref>). Indeed, metastatic nodules were detected in the lung of 63.1&#x00025; (12/19) of PyMT PAI-1 WT mice and 52.2&#x00025; of PymT PAI-1<sup>&#x02212;/&#x02212;</sup> mice (12/23) (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.5421). Similarly, lymph nodes of 73,68&#x00025; (14/19) of PyMT PAI-1 WT mice and 47,8&#x00025; (11/23) of PymT PAI-1<sup>&#x02212;/&#x02212;</sup> mice (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.1203) were infiltrated by tumoral cells.</p><fig id="pone-0009653-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009653.g003</object-id><label>Figure 3</label><caption><title>Primary tumor development and metastatic potential of PyMT mice crossed with PAI-1 WT or PAI-1<sup>&#x02212;/&#x02212;</sup> mice.</title><p>Presented results are from 11- and 14-week mice. (A): Tumor weight and (B): podoplanin positive relative surface in primary tumors observed in PAI-1 WT and PAI-1<sup>&#x02212;/&#x02212;</sup> mice. (C): Percentage of metastasis in lymph nodes (black columns) and lungs (white columns). n&#x0200a;&#x0003d;&#x0200a;16 PAI-1 WT-PyMT and 17 PAI-1<sup>&#x02212;/&#x02212;</sup>-PyMT mice at 14 weeks, 17 PAI-1 WT-PyMT and 9 PAI-1<sup>&#x02212;/&#x02212;</sup>-PyMT mice at 11 weeks. Data are &#x000b1; S.E.M. &#x0002a;P&#x02264;0.05, NS&#x0200a;&#x0003d;&#x0200a;Non Significant.</p></caption><graphic xlink:href="pone.0009653.g003"/></fig><p>In order to quantify the lymphatic vasculature inside primary PyMT tumors, a computer-assisted automatic quantification method was used <xref ref-type="bibr" rid="pone.0009653-Henno1">&#x0005b;27&#x0005d;</xref>. No difference in terms of podoplanin labelling was observed between tumors generated in both genotypes after 14 weeks (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.0945) (<xref ref-type="fig" rid="pone-0009653-g003">Fig. 3C</xref>).</p></sec><sec id="s3c"><title>PAI-1 Deficiency Does Not Affect Inflammation-Related Lymphangiogenesis</title><p>In order to explore PAI-1 impact on the lymphatic vessel recruitment in inflammatory conditions, we applied a model of lymphatic endothelial cell hyperplasia called lymphangioma <xref ref-type="bibr" rid="pone.0009653-Mancardi1">&#x0005b;24&#x0005d;</xref> to PAI-1 WT (n&#x0200a;&#x0003d;&#x0200a;6) and PAI-1<sup>&#x02212;/&#x02212;</sup> (n&#x0200a;&#x0003d;&#x0200a;6) mice. After 4 weeks, mice were sacrified and the lymphangiomas that appeared as white masses underneath the diaphragm were measured. The surface of lymphangioma area was reported to the total area of the organ (percentage of invasion). Macroscopical analyses revealed that the lymphangioma surface was decreased with PAI-1 deficiency (<italic>P</italic>&#x0003c;0.01, <xref ref-type="fig" rid="pone-0009653-g004">Fig. 4A</xref>). Immunohistochemical analyses of these lymphangiomas were assessed with Lyve-1 and CD45 antibodies to label lymphatic vessels and inflammatory cells, respectively. Fibrosis was evaluated through Sirius red staining. Quantification was performed by a semi-automatic computer-assisted method. The microscopical analyses of lymphangioma sections showed that the area covered by lymphatic vessels was similar in PAI-1<sup>&#x02212;/&#x02212;</sup> compared to corresponding wild type mice (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.49, <xref ref-type="fig" rid="pone-0009653-g004">Fig. 4B</xref>). However, we pointed out differences in the lymphatic vessel structure between the experimental groups. The number of vessels per section was 54&#x000b1;5 &#x000b5;m<sup>2</sup> in PAI-1 WT and 31&#x000b1;2 &#x000b5;m<sup>2</sup> in PAI-1<sup>&#x02212;/&#x02212;</sup> (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.0002), and the vessel average surface was 383&#x000b1;43 &#x000b5;m<sup>2</sup> in PAI-1 WT and was 663&#x000b1;57 &#x000b5;m<sup>2</sup> in PAI-1<sup>&#x02212;/&#x02212;</sup> (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.0003). Thus, vessels in PAI-1<sup>&#x02212;/&#x02212;</sup> mice were fewer but larger leading to an equal vessel area than counterparts. No difference was detected regarding the surface occupied by inflammatory cells (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.44, <xref ref-type="fig" rid="pone-0009653-g004">Fig. 4C</xref>). In sharp contrast, decrease of red Sirius stained fibrosis was observed in PAI-1<sup>&#x02212;/&#x02212;</sup> mice (<italic>P</italic>&#x0003c;0.01, <xref ref-type="fig" rid="pone-0009653-g004">Fig. 4D</xref>) and could explain the reduction of the lymphangioma area observed macroscopically in these mutant mice.</p><fig id="pone-0009653-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009653.g004</object-id><label>Figure 4</label><caption><title>Development of lymphangioma in PAI-1 WT or PAI-1<sup>&#x02212;/&#x02212;</sup> mice.</title><p>A macroscopic decrease of lymphangioma is observed in PAI-1<sup>&#x02212;/&#x02212;</sup> as compared to WT (A). Similar recruitment of lymphatic vessels (assessed by Lyve-1 positivity) (B), and of CD45 positive-inflammatory cells (C) was observed in both genotypes. Evaluation of fibrosis was performed by Sirius red staining (D). Representative images are shown on the left and quantifications performed by computerized image analysis are shown on the right Data are &#x000b1; S.E.M (n&#x0200a;&#x0003d;&#x0200a;6). Scale bars: A&#x0200a;&#x0003d;&#x0200a;0.5 mm, B&#x02013;D&#x0200a;&#x0003d;&#x0200a;200 &#x000b5;m, &#x0002a;&#x0002a; P&#x02264;0.01.</p></caption><graphic xlink:href="pone.0009653.g004"/></fig></sec><sec id="s3d"><title>PAI-1 Is Dispensable for Corneal Lymphangiogenesis</title><p>We then extended our study to an additional model of lymphangiogenesis related to inflammation. The corneal assay is an <italic>in vivo</italic> model which consists in a neovascularization induced by burning the central area of mouse cornea <xref ref-type="bibr" rid="pone.0009653-Cursiefen1">&#x0005b;28&#x0005d;</xref>. We previously confirmed the presence of PAI-1 mRNA in corneal lesions (data not shown). No modification of the lymphatic vessel recruitment was observed in the PAI-1<sup>&#x02212;/&#x02212;</sup> mice (n&#x0200a;&#x0003d;&#x0200a;5) compared to the wild type mice (n&#x0200a;&#x0003d;&#x0200a;5) as assessed by the quantification of Lyve-1 labelled lymphatic vessels of the entire cornea (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.3064) (<xref ref-type="fig" rid="pone-0009653-g005">Fig. 5</xref>). Structural features of the lymphatic network developed in the PAI-1 WT or PAI-1<sup>&#x02212;/&#x02212;</sup> mice were also similar since all parameters analysed by computerized image analysis were identical <xref ref-type="bibr" rid="pone.0009653-Blacher1">&#x0005b;26&#x0005d;</xref>: the end-point density reflecting the number of vessels (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.2715), the node density representing the number of branchings (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.4526) and the length density corresponding the total length of the vessels (<italic>P</italic>&#x0200a;&#x0003d;&#x0200a;0.3998).</p><fig id="pone-0009653-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0009653.g005</object-id><label>Figure 5</label><caption><title>Photography and quantification of the Lyve-1 positive-network observed in the corneal assay in PAI-1 WT or PAI-1<sup>&#x02212;/&#x02212;</sup> mice.</title><p>The node, end-point and length densities are presented for both experimental groups with a schematic illustration of each of these measured parameters at the left. The area covered by the lymphatic vessels normalized to the total corneal area (relative surface, &#x00025;) is also indicated. These parameters quantified by computerized image analysis are defined in Material and <xref ref-type="sec" rid="s2">Methods</xref>. Data are &#x000b1; S.E.M (n&#x0200a;&#x0003d;&#x0200a;5). Scale bar&#x0200a;&#x0003d;&#x0200a;400 &#x000b5;m, NS&#x0200a;&#x0003d;&#x0200a;Non Significant.</p></caption><graphic xlink:href="pone.0009653.g005"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>The plasminogen activation system is largely implicated in pathological angiogenic processes. The genetic deficiency of PAI-1 in mice is associated to impaired blood vascularisation in several experimental models <xref ref-type="bibr" rid="pone.0009653-Leik1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Gutierrez1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-McMahon1">&#x0005b;18&#x0005d;</xref> such as cancer <xref ref-type="bibr" rid="pone.0009653-Maillard1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Bajou2">&#x0005b;13&#x0005d;</xref> and choroidal angiogenesis models <xref ref-type="bibr" rid="pone.0009653-Lambert1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Lambert2">&#x0005b;14&#x0005d;</xref>. The pivotal role of PAI-1 in pathological angiogenesis led to the expectation that this protease inhibitor regulates also lymphangiogenesis. Surprisingly, we previously reported that neither PAI-1 deficiency nor a pharmacological inhibitor of serine proteases directly affect the endothelial cell sprouting from thoracic duct explants in the lymphatic ring assay <xref ref-type="bibr" rid="pone.0009653-Bruyere1">&#x0005b;29&#x0005d;</xref>. Nevertheless, this finding does not exclude a putative role of PAI-1 <italic>in vivo</italic> depending on the <italic>in vivo</italic> microenvironment and for instance, on an inflammatory reaction which is often associated with lymphangiogenesis. To address this important issue, we applied to PAI-1 deficient mice two models of breast cancer and two models of inflammation-related lymphangiogenesis. We found that PAI-1 is not essential for pathological lymphangiogenesis.</p><p>We first used a orthotopic graft model of VEGF-C overexpressing-mammary carcinoma cells (MCF7). VEGF-C has been indeed reported to promote tumor growth in SCID <xref ref-type="bibr" rid="pone.0009653-Karpanen2">&#x0005b;22&#x0005d;</xref> and nude mice <xref ref-type="bibr" rid="pone.0009653-Mattila1">&#x0005b;23&#x0005d;</xref>. Tumor lymphangiogenesis was increased in VEGF-C MCF7 tumors injected in nude mice and lymph node metastasis were found more frequently <xref ref-type="bibr" rid="pone.0009653-Mattila1">&#x0005b;23&#x0005d;</xref>. Similar results were reported with VEGF-C overexpressing MDA-MB-435 <xref ref-type="bibr" rid="pone.0009653-Skobe1">&#x0005b;30&#x0005d;</xref>. In the present study, MCF7 cells overexpressing or not VEGF-C were inoculated into RAG-1<sup>&#x02212;/&#x02212;</sup> immunodeficient mice crossed with PAI-1 WT or PAI-1 deficient mice. In accordance with previous reports <xref ref-type="bibr" rid="pone.0009653-Karpanen2">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Mattila1">&#x0005b;23&#x0005d;</xref>, we confirmed the increased growth rate of VEGF-C expressing tumors. The pro-tumoral effect of VEGF-C was previously attributed to a better oxygenation due to a slight angiogenic response or a decreased intratumoral pressure because of the increased number of lymphatic vessels. It is worth noting that the mice background and the immunodeficiency rate are essential factors influencing the lymph node dissemination. Indeed, the propensity of VEGF-C expressing cells to disseminate into lymph node was higher in nude mice <xref ref-type="bibr" rid="pone.0009653-Mattila1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Skobe1">&#x0005b;30&#x0005d;</xref> than in SCID mice <xref ref-type="bibr" rid="pone.0009653-Karpanen2">&#x0005b;22&#x0005d;</xref> or RAG-1<sup>&#x02212;/&#x02212;</sup> mice (the present study). Since these mice differ in their B-lymphocyte status, it suggests that B lymphocytes might contribute to lymph node dissemination of cancerous cells. Accordingly, the requirement of B-lymphocytes was also observed in a lymphangiogenesis model of mycoplasma infection of the pulmonary tract <xref ref-type="bibr" rid="pone.0009653-Aurora1">&#x0005b;31&#x0005d;</xref>.</p><p>In agreement with previous studies, PAI-1 deficiency was associated with decreased tumor development <xref ref-type="bibr" rid="pone.0009653-Maillard1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-McMahon1">&#x0005b;18&#x0005d;</xref>. We further analysed the lymphatic invasion of these tumors and their dissemination into lymph nodes. Although VEGF-C expression led to an enhancement of lymphatic vessel numbers, no difference was observed in PAI-1 WT and PAI-1<sup>&#x02212;/&#x02212;</sup> mice. Moreover, both genotypes showed a similar rate of lymph node metastasis. These data clearly demonstrate that PAI-1 is not implicated in tumoral lymphangiogenesis. Moreover, our data are in line with a previous study on PyMT transgenic mice showing that the primary tumor growth was not significantly affected by PAI-1 deficiency and neither was the lung metastatic burden <xref ref-type="bibr" rid="pone.0009653-Almholt1">&#x0005b;21&#x0005d;</xref>. We now demonstrate that PAI-1 is dispensable for tumoral lymphangiogenesis by using the PyMT and PAI-1 double transgenic mice.</p><p>Knowing that inflammation influences cancer progression <xref ref-type="bibr" rid="pone.0009653-Hojilla1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-DeNardo1">&#x0005b;33&#x0005d;</xref> and that lymphangiogenesis and inflammation processes are closely related, we applied a model of lymphangioma to PAI-1<sup>&#x02212;/&#x02212;</sup> mice. This system consists in a benign hyperplasia of lymphatic vessels induced by the injection of Freund adjuvant and is often used to isolate lymphatic endothelial cells <xref ref-type="bibr" rid="pone.0009653-Mancardi1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Nakamura1">&#x0005b;34&#x0005d;</xref>. In this system, the inflammatory reaction induced by Freund adjuvant relies on the recruitment of leukocytes by cytokines secreted by cells of the peritoneum <xref ref-type="bibr" rid="pone.0009653-PhilipJoet1">&#x0005b;35&#x0005d;</xref>. In PAI-1 deficient mice, we observed a macroscopic decrease of the lymphangioma formation as compared to PAI-1 WT mice. This effect could be ascribed to a reduction of fibrosis rather than to a decrease in lymphatic vessel recruitment. Accordingly, PAI-1 deficiency slowed down the fibrotic reaction in different models <xref ref-type="bibr" rid="pone.0009653-ChuangTsai1">&#x0005b;36&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Oda1">&#x0005b;37&#x0005d;</xref> by accelerating plasmin-mediated proteolysis <xref ref-type="bibr" rid="pone.0009653-ChuangTsai1">&#x0005b;36&#x0005d;</xref> or by influencing macrophage or myofibroblast recruitment <xref ref-type="bibr" rid="pone.0009653-Oda1">&#x0005b;37&#x0005d;</xref>. The lack of PAI-1 effect on inflammation related lymphangiogenesis was further confirmed by similar injury-induced corneal lymphangiogenesis observed in PAI-1<sup>&#x02212;/&#x02212;</sup> and PAI-1 WT mice. The increased lymphatic vessel size observed in lymphangioma of PAI-1<sup>&#x02212;/&#x02212;</sup> mice is intriguing. However, note that this variation in vessel structure is associated with a reduction of matrix deposition which may influence vessel branching. Studies on mammary gland morphogenesis revealed that the collagen deposition inhibition reduced developing tubular structure bifurcations <xref ref-type="bibr" rid="pone.0009653-Wiseman1">&#x0005b;38&#x0005d;</xref>. The matrix proteolytic breakdown could compromise the scaffold mechanical integrity necessary to counter endothelial cells-generated forces during the tube formation process <xref ref-type="bibr" rid="pone.0009653-Lu1">&#x0005b;39&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0009653-Ghajar1">&#x0005b;40&#x0005d;</xref>. Thus, the difference in vessel structure likely relies on PAI-1-regulated fibrotic response rather than on a direct effect of PAI-1 on lymphangiogenesis.</p><p>The present study using genetic approaches provide for the first time evidences that in contrast to its pivotal role in pathological angiogenesis, PAI-1 is dispensable in pathological lymphangiogenesis in tumoral situations as well as in inflammatory disorders. This clearly demonstrates that distinct molecular pathways govern angiogenesis and lymphangiogenesis and that PAI-1 plays distinct roles in the remodelling of both circulation systems in pathological conditions. Providing that PAI-1 antagonists are used to inhibit angiogenesis <xref ref-type="bibr" rid="pone.0009653-Andreasen1">&#x0005b;41&#x0005d;</xref>, our results reveal that this approach will not have any effect on lymphangiogenesis. Although PAI-1 is dispensable for lymphangiogenesis, it is worth noting that other proteolytic systems are mandatory for this process and particularly matrix metalloproteases such as the MMP-2 whose deficiency impairs lymphangiogenesis in <italic>in vitro</italic> and <italic>in vivo</italic> models <xref ref-type="bibr" rid="pone.0009653-Bruyere1">&#x0005b;29&#x0005d;</xref>.</p></sec></body><back><ack><p>The authors acknowledge G. Roland, F. Olivier, I. Dasoul, E. Feyereisen, L. Poma and P. Gavitelli for their excellent technical assistance.</p></ack><ref-list><title>References</title><ref id="pone.0009653-Karpanen1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpanen</surname><given-names>T</given-names></name><name><surname>Alitalo</surname><given-names>K</given-names></name></person-group><year>2008</year><article-title>Molecular biology and pathology of lymphangiogenesis.</article-title><source>Annu Rev Pathol</source><volume>3</volume><fpage>367</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">18039141</pub-id></mixed-citation></ref><ref id="pone.0009653-Thiele1"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiele</surname><given-names>W</given-names></name><name><surname>Sleeman</surname><given-names>JP</given-names></name></person-group><year>2006</year><article-title>Tumor-induced lymphangiogenesis: A target for cancer therapy?</article-title><source>J Biotechnol</source><volume>124</volume><fpage>224</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">16497404</pub-id></mixed-citation></ref><ref id="pone.0009653-Thaunat1"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thaunat</surname><given-names>O</given-names></name><name><surname>Kerjaschki</surname><given-names>D</given-names></name><name><surname>Nicoletti</surname><given-names>A</given-names></name></person-group><year>2006</year><article-title>Is defective lymphatic drainage a trigger for lymphoid neogenesis?</article-title><source>Trends Immunol</source><volume>27</volume><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">16920402</pub-id></mixed-citation></ref><ref id="pone.0009653-Dass1"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dass</surname><given-names>K</given-names></name><name><surname>Ahmad</surname><given-names>A</given-names></name><name><surname>Azmi</surname><given-names>AS</given-names></name><name><surname>Sarkar</surname><given-names>SH</given-names></name><name><surname>Sarkar</surname><given-names>FH</given-names></name></person-group><year>2008</year><article-title>Evolving role of uPA/uPAR system in human cancers.</article-title><source>Cancer Treat Rev</source><volume>34</volume><fpage>122</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">18162327</pub-id></mixed-citation></ref><ref id="pone.0009653-Lee1"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C-C</given-names></name><name><surname>Huang</surname><given-names>T-S</given-names></name></person-group><year>2005</year><article-title>Plasminogen Activator Inhibitor-1: The expression, Biological Functions, and Effects on Tumorigenesis and Tumor Cell Adhesion and Migration.</article-title><source>Journal of Cancer Molecules</source><volume>1</volume><fpage>25</fpage><lpage>36</lpage></mixed-citation></ref><ref id="pone.0009653-Dano1"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dano</surname><given-names>K</given-names></name><name><surname>Behrendt</surname><given-names>N</given-names></name><name><surname>Hoyer-Hansen</surname><given-names>G</given-names></name><name><surname>Johnsen</surname><given-names>M</given-names></name><name><surname>Lund</surname><given-names>LR</given-names></name><etal/></person-group><year>2005</year><article-title>Plasminogen activation and cancer.</article-title><source>Thromb Haemost</source><volume>93</volume><fpage>676</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">15841311</pub-id></mixed-citation></ref><ref id="pone.0009653-Czekay1"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czekay</surname><given-names>RP</given-names></name><name><surname>Loskutoff</surname><given-names>DJ</given-names></name></person-group><year>2004</year><article-title>Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment.</article-title><source>Exp Biol Med (Maywood)</source><volume>229</volume><fpage>1090</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">15564434</pub-id></mixed-citation></ref><ref id="pone.0009653-Bajou1"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajou</surname><given-names>K</given-names></name><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Laug</surname><given-names>WE</given-names></name><name><surname>Maillard</surname><given-names>C</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name><etal/></person-group><year>2008</year><article-title>Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.</article-title><source>Cancer Cell</source><volume>14</volume><fpage>324</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">18835034</pub-id></mixed-citation></ref><ref id="pone.0009653-Leik1"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leik</surname><given-names>CE</given-names></name><name><surname>Su</surname><given-names>EJ</given-names></name><name><surname>Nambi</surname><given-names>P</given-names></name><name><surname>Crandall</surname><given-names>DL</given-names></name><name><surname>Lawrence</surname><given-names>DA</given-names></name></person-group><year>2006</year><article-title>Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.</article-title><source>J Thromb Haemost</source><volume>4</volume><fpage>2710</fpage><lpage>2715</lpage><pub-id pub-id-type="pmid">17010152</pub-id></mixed-citation></ref><ref id="pone.0009653-Maillard1"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maillard</surname><given-names>C</given-names></name><name><surname>Jost</surname><given-names>M</given-names></name><name><surname>Romer</surname><given-names>MU</given-names></name><name><surname>Brunner</surname><given-names>N</given-names></name><name><surname>Houard</surname><given-names>X</given-names></name><etal/></person-group><year>2005</year><article-title>Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.</article-title><source>Neoplasia</source><volume>7</volume><fpage>57</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">15720817</pub-id></mixed-citation></ref><ref id="pone.0009653-Lambert1"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>V</given-names></name><name><surname>Munaut</surname><given-names>C</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name><name><surname>Frankenne</surname><given-names>F</given-names></name><name><surname>Bajou</surname><given-names>K</given-names></name><etal/></person-group><year>2001</year><article-title>Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.</article-title><source>FASEB J</source><volume>15</volume><fpage>1021</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">11292663</pub-id></mixed-citation></ref><ref id="pone.0009653-Gutierrez1"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez</surname><given-names>LS</given-names></name><name><surname>Schulman</surname><given-names>A</given-names></name><name><surname>Brito-Robinson</surname><given-names>T</given-names></name><name><surname>Noria</surname><given-names>F</given-names></name><name><surname>Ploplis</surname><given-names>VA</given-names></name><etal/></person-group><year>2000</year><article-title>Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.</article-title><source>Cancer Res</source><volume>60</volume><fpage>5839</fpage><lpage>5847</lpage><pub-id pub-id-type="pmid">11059781</pub-id></mixed-citation></ref><ref id="pone.0009653-Bajou2"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajou</surname><given-names>K</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name><name><surname>Gerard</surname><given-names>RD</given-names></name><name><surname>Masson</surname><given-names>V</given-names></name><name><surname>Brunner</surname><given-names>N</given-names></name><etal/></person-group><year>1998</year><article-title>Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.</article-title><source>Nat Med</source><volume>4</volume><fpage>923</fpage><lpage>928</lpage><pub-id pub-id-type="pmid">9701244</pub-id></mixed-citation></ref><ref id="pone.0009653-Lambert2"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambert</surname><given-names>V</given-names></name><name><surname>Munaut</surname><given-names>C</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Gerard</surname><given-names>RD</given-names></name><name><surname>Declerck</surname><given-names>PJ</given-names></name><etal/></person-group><year>2003</year><article-title>Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials.</article-title><source>Invest Ophthalmol Vis Sci</source><volume>44</volume><fpage>2791</fpage><lpage>2797</lpage><pub-id pub-id-type="pmid">12766088</pub-id></mixed-citation></ref><ref id="pone.0009653-Ossowski1"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ossowski</surname><given-names>L</given-names></name><name><surname>Reich</surname><given-names>E</given-names></name></person-group><year>1983</year><article-title>Antibodies to plasminogen activator inhibit human tumor metastasis.</article-title><source>Cell</source><volume>35</volume><fpage>611</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">6418388</pub-id></mixed-citation></ref><ref id="pone.0009653-Tsuchiya1"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchiya</surname><given-names>H</given-names></name><name><surname>Katsuo</surname><given-names>S</given-names></name><name><surname>Matsuda</surname><given-names>E</given-names></name><name><surname>Sunayama</surname><given-names>C</given-names></name><name><surname>Tomita</surname><given-names>K</given-names></name><etal/></person-group><year>1995</year><article-title>The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.</article-title><source><italic>Gen Diagn Pathol</italic></source><volume>141</volume><fpage>41</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">8542506</pub-id></mixed-citation></ref><ref id="pone.0009653-Devy1"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devy</surname><given-names>L</given-names></name><name><surname>Blacher</surname><given-names>S</given-names></name><name><surname>Grignet-Debrus</surname><given-names>C</given-names></name><name><surname>Bajou</surname><given-names>K</given-names></name><name><surname>Masson</surname><given-names>V</given-names></name><etal/></person-group><year>2002</year><article-title>The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.</article-title><source><italic>FASEB J</italic></source><volume>16</volume><fpage>147</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">11818362</pub-id></mixed-citation></ref><ref id="pone.0009653-McMahon1"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>GA</given-names></name><name><surname>Petitclerc</surname><given-names>E</given-names></name><name><surname>Stefansson</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>E</given-names></name><name><surname>Wong</surname><given-names>MK</given-names></name><etal/></person-group><year>2001</year><article-title>Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.</article-title><source><italic>J Biol Chem</italic></source><volume>276</volume><fpage>33964</fpage><lpage>33968</lpage><pub-id pub-id-type="pmid">11441025</pub-id></mixed-citation></ref><ref id="pone.0009653-Bajou3"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajou</surname><given-names>K</given-names></name><name><surname>Maillard</surname><given-names>C</given-names></name><name><surname>Jost</surname><given-names>M</given-names></name><name><surname>Lijnen</surname><given-names>RH</given-names></name><name><surname>Gils</surname><given-names>A</given-names></name><etal/></person-group><year>2004</year><article-title>Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.</article-title><source><italic>Oncogene</italic></source><volume>23</volume><fpage>6986</fpage><lpage>6990</lpage><pub-id pub-id-type="pmid">15286708</pub-id></mixed-citation></ref><ref id="pone.0009653-Jost1"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jost</surname><given-names>M</given-names></name><name><surname>Maillard</surname><given-names>C</given-names></name><name><surname>Lecomte</surname><given-names>J</given-names></name><name><surname>Lambert</surname><given-names>V</given-names></name><name><surname>Tjwa</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I.</article-title><source><italic>Am J Pathol</italic></source><volume>171</volume><fpage>1369</fpage><lpage>1380</lpage><pub-id pub-id-type="pmid">17717143</pub-id></mixed-citation></ref><ref id="pone.0009653-Almholt1"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almholt</surname><given-names>K</given-names></name><name><surname>Nielsen</surname><given-names>BS</given-names></name><name><surname>Frandsen</surname><given-names>TL</given-names></name><name><surname>Brunner</surname><given-names>N</given-names></name><name><surname>Dano</surname><given-names>K</given-names></name><etal/></person-group><year>2003</year><article-title>Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.</article-title><source><italic>Oncogene</italic></source><volume>22</volume><fpage>4389</fpage><lpage>4397</lpage><pub-id pub-id-type="pmid">12853975</pub-id></mixed-citation></ref><ref id="pone.0009653-Karpanen2"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karpanen</surname><given-names>T</given-names></name><name><surname>Egeblad</surname><given-names>M</given-names></name><name><surname>Karkkainen</surname><given-names>MJ</given-names></name><name><surname>Kubo</surname><given-names>H</given-names></name><name><surname>Yla-Herttuala</surname><given-names>S</given-names></name><etal/></person-group><year>2001</year><article-title>Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth.</article-title><source><italic>Cancer Res</italic></source><volume>61</volume><fpage>1786</fpage><lpage>1790</lpage><pub-id pub-id-type="pmid">11280723</pub-id></mixed-citation></ref><ref id="pone.0009653-Mattila1"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattila</surname><given-names>MM</given-names></name><name><surname>Ruohola</surname><given-names>JK</given-names></name><name><surname>Karpanen</surname><given-names>T</given-names></name><name><surname>Jackson</surname><given-names>DG</given-names></name><name><surname>Alitalo</surname><given-names>K</given-names></name><etal/></person-group><year>2002</year><article-title>VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors.</article-title><source><italic>Int J Cancer</italic></source><volume>98</volume><fpage>946</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">11948478</pub-id></mixed-citation></ref><ref id="pone.0009653-Mancardi1"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancardi</surname><given-names>S</given-names></name><name><surname>Stanta</surname><given-names>G</given-names></name><name><surname>Dusetti</surname><given-names>N</given-names></name><name><surname>Bestagno</surname><given-names>M</given-names></name><name><surname>Jussila</surname><given-names>L</given-names></name><etal/></person-group><year>1999</year><article-title>Lymphatic endothelial tumors induced by intraperitoneal injection of incomplete Freund's adjuvant.</article-title><source><italic>Exp Cell Res</italic></source><volume>246</volume><fpage>368</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">9925752</pub-id></mixed-citation></ref><ref id="pone.0009653-Fenton1"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenton</surname><given-names>BM</given-names></name><name><surname>Zweifach</surname><given-names>BW</given-names></name><name><surname>Worthen</surname><given-names>DM</given-names></name></person-group><year>1979</year><article-title>Quantitative morphometry of conjunctival microcirculation in diabetes mellitus.</article-title><source><italic>Microvasc Res</italic></source><volume>18</volume><fpage>153</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">491983</pub-id></mixed-citation></ref><ref id="pone.0009653-Blacher1"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blacher</surname><given-names>S</given-names></name><name><surname>Detry</surname><given-names>B, FB</given-names></name><name><surname>Foidart</surname><given-names>JM</given-names></name><name><surname>Noel</surname><given-names>A</given-names></name></person-group><year>2009</year><article-title>Additional parameters for the morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts.</article-title><source><italic>Exp Eye Res</italic></source><volume>89</volume><fpage>274</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">19285069</pub-id></mixed-citation></ref><ref id="pone.0009653-Henno1"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henno</surname><given-names>A</given-names></name><name><surname>Blacher</surname><given-names>S</given-names></name><name><surname>Lambert</surname><given-names>C</given-names></name><name><surname>Colige</surname><given-names>A</given-names></name><name><surname>Seidel</surname><given-names>L</given-names></name><etal/></person-group><year>2008</year><article-title>Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis.</article-title><source><italic>Br J Dermatol</italic></source></mixed-citation></ref><ref id="pone.0009653-Cursiefen1"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cursiefen</surname><given-names>C</given-names></name><name><surname>Maruyama</surname><given-names>K</given-names></name><name><surname>Jackson</surname><given-names>DG</given-names></name><name><surname>Streilein</surname><given-names>JW</given-names></name><name><surname>Kruse</surname><given-names>FE</given-names></name></person-group><year>2006</year><article-title>Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation.</article-title><source><italic>Cornea</italic></source><volume>25</volume><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">16670483</pub-id></mixed-citation></ref><ref id="pone.0009653-Bruyere1"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruyere</surname><given-names>F</given-names></name><name><surname>Melen-Lamalle</surname><given-names>L</given-names></name><name><surname>Blacher</surname><given-names>S</given-names></name><name><surname>Roland</surname><given-names>G</given-names></name><name><surname>Thiry</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>Modeling lymphangiogenesis in a three-dimensional culture system.</article-title><source><italic>Nat Methods</italic></source><volume>5</volume><fpage>431</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">18425139</pub-id></mixed-citation></ref><ref id="pone.0009653-Skobe1"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skobe</surname><given-names>M</given-names></name><name><surname>Hawighorst</surname><given-names>T</given-names></name><name><surname>Jackson</surname><given-names>DG</given-names></name><name><surname>Prevo</surname><given-names>R</given-names></name><name><surname>Janes</surname><given-names>L</given-names></name><etal/></person-group><year>2001</year><article-title>Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis.</article-title><source><italic>Nat Med</italic></source><volume>7</volume><fpage>192</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">11175850</pub-id></mixed-citation></ref><ref id="pone.0009653-Aurora1"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aurora</surname><given-names>AB</given-names></name><name><surname>Baluk</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Sidhu</surname><given-names>SS</given-names></name><name><surname>Dolganov</surname><given-names>GM</given-names></name><etal/></person-group><year>2005</year><article-title>Immune complex-dependent remodeling of the airway vasculature in response to a chronic bacterial infection.</article-title><source><italic>J Immunol</italic></source><volume>175</volume><fpage>6319</fpage><lpage>6326</lpage><pub-id pub-id-type="pmid">16272283</pub-id></mixed-citation></ref><ref id="pone.0009653-Hojilla1"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hojilla</surname><given-names>CV</given-names></name><name><surname>Wood</surname><given-names>GA</given-names></name><name><surname>Khokha</surname><given-names>R</given-names></name></person-group><year>2008</year><article-title>Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer.</article-title><source><italic>Breast Cancer Res</italic></source><volume>10</volume><fpage>205</fpage><pub-id pub-id-type="pmid">18394187</pub-id></mixed-citation></ref><ref id="pone.0009653-DeNardo1"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeNardo</surname><given-names>DG</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Coussens</surname><given-names>LM</given-names></name></person-group><year>2008</year><article-title>Immune cells as mediators of solid tumor metastasis.</article-title><source><italic>Cancer Metastasis Rev</italic></source><volume>27</volume><fpage>11</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">18066650</pub-id></mixed-citation></ref><ref id="pone.0009653-Nakamura1"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>ES</given-names></name><name><surname>Koizumi</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Saiki</surname><given-names>I</given-names></name></person-group><year>2004</year><article-title>Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270.</article-title><source><italic>Cancer Sci</italic></source><volume>95</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">14720323</pub-id></mixed-citation></ref><ref id="pone.0009653-PhilipJoet1"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philip-Joet</surname><given-names>F</given-names></name><name><surname>Alessi</surname><given-names>MC</given-names></name><name><surname>Philip-Joet</surname><given-names>C</given-names></name><name><surname>Aillaud</surname><given-names>M</given-names></name><name><surname>Barriere</surname><given-names>JR</given-names></name><etal/></person-group><year>1995</year><article-title>Fibrinolytic and inflammatory processes in pleural effusions.</article-title><source><italic>Eur Respir J</italic></source><volume>8</volume><fpage>1352</fpage><lpage>1356</lpage><pub-id pub-id-type="pmid">7489803</pub-id></mixed-citation></ref><ref id="pone.0009653-ChuangTsai1"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuang-Tsai</surname><given-names>S</given-names></name><name><surname>Sisson</surname><given-names>TH</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Tsai</surname><given-names>CG</given-names></name><name><surname>Subbotina</surname><given-names>NM</given-names></name><etal/></person-group><year>2003</year><article-title>Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1.</article-title><source><italic>Am J Pathol</italic></source><volume>163</volume><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">12875966</pub-id></mixed-citation></ref><ref id="pone.0009653-Oda1"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>T</given-names></name><name><surname>Jung</surname><given-names>YO</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Lopez-Guisa</surname><given-names>JM</given-names></name><etal/></person-group><year>2001</year><article-title>PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction.</article-title><source><italic>Kidney Int</italic></source><volume>60</volume><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">11473641</pub-id></mixed-citation></ref><ref id="pone.0009653-Wiseman1"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiseman</surname><given-names>BS</given-names></name><name><surname>Sternlicht</surname><given-names>MD</given-names></name><name><surname>Lund</surname><given-names>LR</given-names></name><name><surname>Alexander</surname><given-names>CM</given-names></name><name><surname>Mott</surname><given-names>J</given-names></name><etal/></person-group><year>2003</year><article-title>Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis.</article-title><source><italic>J Cell Biol</italic></source><volume>162</volume><fpage>1123</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">12975354</pub-id></mixed-citation></ref><ref id="pone.0009653-Lu1"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><year>2008</year><article-title>Patterning mechanisms of branched organs.</article-title><source><italic>Science</italic></source><volume>322</volume><fpage>1506</fpage><lpage>1509</lpage><pub-id pub-id-type="pmid">19056977</pub-id></mixed-citation></ref><ref id="pone.0009653-Ghajar1"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghajar</surname><given-names>CM</given-names></name><name><surname>George</surname><given-names>SC</given-names></name><name><surname>Putnam</surname><given-names>AJ</given-names></name></person-group><year>2008</year><article-title>Matrix metalloproteinase control of capillary morphogenesis.</article-title><source><italic>Crit Rev Eukaryot Gene Expr</italic></source><volume>18</volume><fpage>251</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">18540825</pub-id></mixed-citation></ref><ref id="pone.0009653-Andreasen1"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreasen</surname><given-names>PA</given-names></name><name><surname>Egelund</surname><given-names>R</given-names></name><name><surname>Petersen</surname><given-names>HH</given-names></name></person-group><year>2000</year><article-title>The plasminogen activation system in tumor growth, invasion, and metastasis.</article-title><source><italic>Cell Mol Life Sci</italic></source><volume>57</volume><fpage>25</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">10949579</pub-id></mixed-citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by grants from the European Union Framework Program projects (FP7-2007-2011 &#x0201c;MICROENVIMET&#x0201d; No 201279), the Fonds de la Recherche Scientifique M&#x000e9;dicale, the Fonds National de la Recherche Scientifique (F.N.R.S., Belgium), the Fondation contre le Cancer, the Fonds sp&#x000e9;ciaux de la Recherche (University of Li&#x000e8;ge), the Centre Anticanc&#x000e9;reux pr&#x000e8;s l'Universit&#x000e9; de Li&#x000e8;ge, the Fonds L&#x000e9;on Fredericq (University of Li&#x000e8;ge), the D.G.T.R.E. from the &#x000ab;R&#x000e9;gion Wallonne&#x000bb;, the Interuniversity Attraction Poles Programme - Belgian Science Policy (Brussels, Belgium). FB, BD, AM and JL are recipients of a Televie-FNRS grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>